<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65327">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755338</url>
  </required_header>
  <id_info>
    <org_study_id>2012-004232-37</org_study_id>
    <nct_id>NCT01755338</nct_id>
  </id_info>
  <brief_title>Effect of Steroids on Cerebrospinal Fluid Markers of Inflammation and Neuronal Damage After Surgical Aortic Valve Replacement</brief_title>
  <official_title>Effect of Steroids on Cerebrospinal Fluid Markers of Inflammation and Neuronal Damage After Surgical Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <authority>Sweden: Swedish Research Council</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if methylprednisolone is effective in reducing
      the cerebral inflammatory response after open heart surgery with cardiopulmonary bypass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a previous study we found that patients undergoing aortic valve surgery had elevated
      cerebrospinal inflammatory markers. In this study we aim to investigate if this inflammatory
      response can be reduced after treatment with steroids.

      20 patients will be randomized to intraoperative treatment with either placebo or
      methylprednisolone 15mg/kg. CSF and blood will be collected the day before and the day after
      surgery, analyzed for markers of inflammation (IL-6, IL-8), neuronal damage (S-100) and
      blood brain barrier function (alb).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in cerebrospinal fluid (CSF) levels of IL-6, IL-8, S100B, alb</measure>
    <time_frame>24h after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative/intraoperative insulin demand</measure>
    <time_frame>24h after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylprednisolone i.v. 15mg/kg x 1 intraoperative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo i.v., x1, intraoperative</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>15mg/kg i.v.</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <other_name>Solu Medrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective aortic surgery +/- coronary artery bypass grafting (CABG)

        Exclusion Criteria:

          -  coagulopathy

          -  preoperative neurologic deficit

          -  uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven-Erik Ricksten, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mattias Danielson, MD</last_name>
    <phone>+46313427452</phone>
    <email>mattias.danielsson@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sven Erik Ricksten, Professor</last_name>
    <phone>+46313427433</phone>
    <email>sven-erik.ricksten@aniv.gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>GÃ¶teborg</city>
        <state>VGR</state>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattias Danielson, MD</last_name>
      <phone>+46313427452</phone>
      <email>mattias.danielsson@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Mattias Danielson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>December 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Mattias Danielson</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>cerebrospinal fluid</keyword>
  <keyword>inflammatory markers</keyword>
  <keyword>heart surgery</keyword>
  <keyword>neuronal damage</keyword>
  <keyword>blood brain barrier</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
